APA (7th ed.) Citation

BA, W., AC, L., JL, D., S, S., L, C., SW, A., . . . SL, L. (2023). Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial. Journal of Alzheimer's disease reports, 7(1), 1015. https://doi.org/10.3233/ADR-230012

Chicago Style (17th ed.) Citation

BA, Willis, et al. "Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial." Journal of Alzheimer's Disease Reports 7, no. 1 (2023): 1015. https://doi.org/10.3233/ADR-230012.

MLA (9th ed.) Citation

BA, Willis, et al. "Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical Trial." Journal of Alzheimer's Disease Reports, vol. 7, no. 1, 2023, p. 1015, https://doi.org/10.3233/ADR-230012.